Inventor
KAPTEIN ALLARD
NL16 patents
⚠️ This page may combine multiple inventors who share the name “KAPTEIN ALLARD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACERTA PHARMA BV
10 patentsUS10272083B2Apr 30, 2019
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV14 citations93
US11771696B2Oct 3, 2023
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV5 citations85
US11090302B2Aug 17, 2021
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV4 citations83
US9949971B2Apr 24, 2018
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
ACERTA PHARMA BV11 citations83
US11654143B2May 23, 2023
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
ACERTA PHARMA BV3 citations72
US11166951B2Nov 9, 2021
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
ACERTA PHARMA BV2 citations72
US10328080B2Jun 25, 2019
Therapeutic combination of PI3K inhibitor and a BTK inhibitor
ACERTA PHARMA BV6 citations72
US12263164B2Apr 1, 2025
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV0 citations62
US11154554B2Oct 26, 2021
Therapeutic combinations of a MEK inhibitor and a BTK inhibitor
ACERTA PHARMA BV0 citations51
US10858364B2Dec 8, 2020
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
ACERTA PHARMA BV0 citations45